Smoking/Vaping Cessation Strategies for Nicotine Withdrawal
(VASP Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
The proposed research, which will systematically and comprehensively characterize the withdrawal among daily vapers compared to daily smokers of combustible cigarettes, filling critical gaps in the understanding of electronic nicotine delivery systems (ENDS) dependence/abuse liability and contributing to the development of therapies for tobacco/nicotine use, the leading preventable cause of death in the US.
Will I have to stop taking my current medications?
The trial requires that you do not use any smoking cessation medication and excludes those on antipsychotic medications. Other medications are not specifically mentioned, so it's best to discuss your current medications with the trial team.
Is nicotine replacement therapy (NRT) safe for humans?
How does this treatment for nicotine withdrawal differ from others?
This treatment is unique because it focuses on specific strategies for managing nicotine withdrawal symptoms, potentially involving novel combinations or dosages of nicotine replacement therapies (NRTs) that are not standard. Unlike traditional NRTs, which are often used alone, this approach may combine different forms or higher doses to better address cravings and withdrawal symptoms.678910
What data supports the effectiveness of the treatment for nicotine withdrawal?
Who Is on the Research Team?
Larry Hawk, PhD
Principal Investigator
University at Buffalo
Are You a Good Fit for This Trial?
This trial is for daily vapers or smokers with a nicotine level of 200+ ng/mL, who've been using these products for over 6 months. It's not open to those who use other tobacco products frequently, have high alcohol use scores, severe substance dependencies (excluding tobacco/nicotine), are on smoking cessation or antipsychotic meds, have major depression/suicide risk, or are pregnant.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Lab Visits
Participants complete two 4-hour lab visits, including ad lib use and abstinent visits
Assessment
Multi-measure, multi-method assessments of withdrawal facets such as negative affect, craving, and difficulty concentrating
Follow-up
Participants are monitored for safety and effectiveness after the main assessments
What Are the Treatments Tested in This Trial?
Interventions
- Acute (24-hour) abstinence
- Ad libitum smoking/vaping
Find a Clinic Near You
Who Is Running the Clinical Trial?
State University of New York at Buffalo
Lead Sponsor
National Institute on Drug Abuse (NIDA)
Collaborator
Roswell Park Cancer Institute
Collaborator